'Poorly Drafted' Patent Deals Can't End Janssen Suit: Judge
A Massachusetts federal judge on Tuesday refused to toss Janssen Biotech Inc.'s patent suit targeting Pfizer Inc.'s biosimilar of blockbuster biologic Remicade, despite finding that assignments of patent rights to Janssen...To view the full article, register now.
Already a subscriber? Click here to view full article